Embecta Corp.
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.1B
- Net income
- $95.4M
- Total assets
- $1.1B
- Market cap
- $200.5M
- Gross margin
- 62.6%
- Operating margin
- 22.4%
- Net margin
- 8.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.1B
- Cost of revenue
- $403.6M
- Gross profit
- $676.8M
- Operating expenses
- $434.7M
- Operating income
- $242.1M
- Income tax
- $40.9M
- Net income
- $95.4M
- EPS (basic)
- $1.64
- EPS (diluted)
- $1.62
Balance sheet
- Total assets
- $1.1B
- Current assets
- $631.4M
- Total liabilities
- $1.7B
- Current liabilities
- $261.5M
- Shareholders’ equity
- -$650.6M
Cash flow
- Operating cash flow
- $191.7M
- Investing cash flow
- -$9.3M
- Financing cash flow
- -$226.7M
- Net cash flow
- -$44.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $200.5M
- P/E ratio
- 2.1
- EPS (diluted)
- $1.62
- Dividend yield
- 1.2%
- Shares outstanding
- 60.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 21, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $95.4M in FY2025.
- Revenue declined 4% from FY2022 to FY2025.
- Gross margin of 62.6%, net margin 8.8%.
- Trading 78% below its 52-week high.
- Pays a dividend yielding about 1.2% annually.
- Valued at a price-to-earnings (P/E) ratio of 2.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Embecta Corp..
Write a review
News about Embecta Corp.
News & sentiment via Polygon.io
